Spironolactone use at discharge was associated with improved survival in hospitalized patients with systolic heart failure

Sanae Hamaguchi, Shintaro Kinugawa, Miyuki Tsuchihashi-Makaya, Kazutomo Goto, Daisuke Goto, Takashi Yokota, Satoshi Yamada, Hisashi Yokoshiki, Akira Takeshita, Hiroyuki Tsutsui

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Background: The RALES trial demonstrated that spironolactone improved the prognosis of patients with heart failure (HF). However, it is unknown whether the discharge use of spironolactone is associated with better long-term outcomes among hospitalized systolic HF patients in routine clinical practice. We examined the effects of spironolactone use at discharge on mortality and rehospitalization by comparing with outcomes in patients who did not receive spironolactone. Methods: The JCARE-CARD studied prospectively the characteristics and treatments in a broad sample of patients hospitalized with worsening HF and the outcomes were followed with an average of 2.2 years of follow-up. Results: A total of 946 patients had HF with reduced left ventricular ejection fraction (LVEF) (<40%), among whom spironolactone was prescribed at discharge in 435 patients (46%), but not in 511 patients (54%). The mean age was 66.3 years and 72.2% were male. Etiology was ischemic in 39.7% and mean LVEF was 27.1%. After adjustment for covariates, discharge use of spironolactone was associated with a significant reduction in all-cause death (adjusted hazard ratio 0.612, P = .020) and cardiac death (adjusted hazard ratio 0.524, P = .013). Conclusions: Among patients with HF hospitalized for systolic dysfunction, spironolactone use at the time of discharge was associated with long-term survival benefit. These findings provide further support for the idea that spironolactone may be useful in patients hospitalized with HF and reduced LVEF.

Original languageEnglish
Pages (from-to)1156-1162
Number of pages7
JournalAmerican heart journal
Volume160
Issue number6
DOIs
Publication statusPublished - Dec 1 2010
Externally publishedYes

Fingerprint

Systolic Heart Failure
Spironolactone
Survival
Heart Failure
Stroke Volume
Cause of Death

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Spironolactone use at discharge was associated with improved survival in hospitalized patients with systolic heart failure. / Hamaguchi, Sanae; Kinugawa, Shintaro; Tsuchihashi-Makaya, Miyuki; Goto, Kazutomo; Goto, Daisuke; Yokota, Takashi; Yamada, Satoshi; Yokoshiki, Hisashi; Takeshita, Akira; Tsutsui, Hiroyuki.

In: American heart journal, Vol. 160, No. 6, 01.12.2010, p. 1156-1162.

Research output: Contribution to journalArticle

Hamaguchi, S, Kinugawa, S, Tsuchihashi-Makaya, M, Goto, K, Goto, D, Yokota, T, Yamada, S, Yokoshiki, H, Takeshita, A & Tsutsui, H 2010, 'Spironolactone use at discharge was associated with improved survival in hospitalized patients with systolic heart failure', American heart journal, vol. 160, no. 6, pp. 1156-1162. https://doi.org/10.1016/j.ahj.2010.08.036
Hamaguchi, Sanae ; Kinugawa, Shintaro ; Tsuchihashi-Makaya, Miyuki ; Goto, Kazutomo ; Goto, Daisuke ; Yokota, Takashi ; Yamada, Satoshi ; Yokoshiki, Hisashi ; Takeshita, Akira ; Tsutsui, Hiroyuki. / Spironolactone use at discharge was associated with improved survival in hospitalized patients with systolic heart failure. In: American heart journal. 2010 ; Vol. 160, No. 6. pp. 1156-1162.
@article{7b496687483243c8975368efb5ec3d36,
title = "Spironolactone use at discharge was associated with improved survival in hospitalized patients with systolic heart failure",
abstract = "Background: The RALES trial demonstrated that spironolactone improved the prognosis of patients with heart failure (HF). However, it is unknown whether the discharge use of spironolactone is associated with better long-term outcomes among hospitalized systolic HF patients in routine clinical practice. We examined the effects of spironolactone use at discharge on mortality and rehospitalization by comparing with outcomes in patients who did not receive spironolactone. Methods: The JCARE-CARD studied prospectively the characteristics and treatments in a broad sample of patients hospitalized with worsening HF and the outcomes were followed with an average of 2.2 years of follow-up. Results: A total of 946 patients had HF with reduced left ventricular ejection fraction (LVEF) (<40{\%}), among whom spironolactone was prescribed at discharge in 435 patients (46{\%}), but not in 511 patients (54{\%}). The mean age was 66.3 years and 72.2{\%} were male. Etiology was ischemic in 39.7{\%} and mean LVEF was 27.1{\%}. After adjustment for covariates, discharge use of spironolactone was associated with a significant reduction in all-cause death (adjusted hazard ratio 0.612, P = .020) and cardiac death (adjusted hazard ratio 0.524, P = .013). Conclusions: Among patients with HF hospitalized for systolic dysfunction, spironolactone use at the time of discharge was associated with long-term survival benefit. These findings provide further support for the idea that spironolactone may be useful in patients hospitalized with HF and reduced LVEF.",
author = "Sanae Hamaguchi and Shintaro Kinugawa and Miyuki Tsuchihashi-Makaya and Kazutomo Goto and Daisuke Goto and Takashi Yokota and Satoshi Yamada and Hisashi Yokoshiki and Akira Takeshita and Hiroyuki Tsutsui",
year = "2010",
month = "12",
day = "1",
doi = "10.1016/j.ahj.2010.08.036",
language = "English",
volume = "160",
pages = "1156--1162",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "6",

}

TY - JOUR

T1 - Spironolactone use at discharge was associated with improved survival in hospitalized patients with systolic heart failure

AU - Hamaguchi, Sanae

AU - Kinugawa, Shintaro

AU - Tsuchihashi-Makaya, Miyuki

AU - Goto, Kazutomo

AU - Goto, Daisuke

AU - Yokota, Takashi

AU - Yamada, Satoshi

AU - Yokoshiki, Hisashi

AU - Takeshita, Akira

AU - Tsutsui, Hiroyuki

PY - 2010/12/1

Y1 - 2010/12/1

N2 - Background: The RALES trial demonstrated that spironolactone improved the prognosis of patients with heart failure (HF). However, it is unknown whether the discharge use of spironolactone is associated with better long-term outcomes among hospitalized systolic HF patients in routine clinical practice. We examined the effects of spironolactone use at discharge on mortality and rehospitalization by comparing with outcomes in patients who did not receive spironolactone. Methods: The JCARE-CARD studied prospectively the characteristics and treatments in a broad sample of patients hospitalized with worsening HF and the outcomes were followed with an average of 2.2 years of follow-up. Results: A total of 946 patients had HF with reduced left ventricular ejection fraction (LVEF) (<40%), among whom spironolactone was prescribed at discharge in 435 patients (46%), but not in 511 patients (54%). The mean age was 66.3 years and 72.2% were male. Etiology was ischemic in 39.7% and mean LVEF was 27.1%. After adjustment for covariates, discharge use of spironolactone was associated with a significant reduction in all-cause death (adjusted hazard ratio 0.612, P = .020) and cardiac death (adjusted hazard ratio 0.524, P = .013). Conclusions: Among patients with HF hospitalized for systolic dysfunction, spironolactone use at the time of discharge was associated with long-term survival benefit. These findings provide further support for the idea that spironolactone may be useful in patients hospitalized with HF and reduced LVEF.

AB - Background: The RALES trial demonstrated that spironolactone improved the prognosis of patients with heart failure (HF). However, it is unknown whether the discharge use of spironolactone is associated with better long-term outcomes among hospitalized systolic HF patients in routine clinical practice. We examined the effects of spironolactone use at discharge on mortality and rehospitalization by comparing with outcomes in patients who did not receive spironolactone. Methods: The JCARE-CARD studied prospectively the characteristics and treatments in a broad sample of patients hospitalized with worsening HF and the outcomes were followed with an average of 2.2 years of follow-up. Results: A total of 946 patients had HF with reduced left ventricular ejection fraction (LVEF) (<40%), among whom spironolactone was prescribed at discharge in 435 patients (46%), but not in 511 patients (54%). The mean age was 66.3 years and 72.2% were male. Etiology was ischemic in 39.7% and mean LVEF was 27.1%. After adjustment for covariates, discharge use of spironolactone was associated with a significant reduction in all-cause death (adjusted hazard ratio 0.612, P = .020) and cardiac death (adjusted hazard ratio 0.524, P = .013). Conclusions: Among patients with HF hospitalized for systolic dysfunction, spironolactone use at the time of discharge was associated with long-term survival benefit. These findings provide further support for the idea that spironolactone may be useful in patients hospitalized with HF and reduced LVEF.

UR - http://www.scopus.com/inward/record.url?scp=78650191506&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650191506&partnerID=8YFLogxK

U2 - 10.1016/j.ahj.2010.08.036

DO - 10.1016/j.ahj.2010.08.036

M3 - Article

C2 - 21146672

AN - SCOPUS:78650191506

VL - 160

SP - 1156

EP - 1162

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 6

ER -